Drug therapy for multiple sclerosis.
作者信息
Tavazzi Eleonora, Rovaris Marco, La Mantia Loredana
机构信息
Multiple Sclerosis Center - Unit of Motor Neurorehabilitation, IRCCS Santa Maria Nascente, Fondazione Don Gnocchi, Milan, Italy.
Multiple Sclerosis Center - Unit of Motor Neurorehabilitation, IRCCS Santa Maria Nascente, Fondazione Don Gnocchi, Milan, Italy
出版信息
CMAJ. 2014 Aug 5;186(11):833-40. doi: 10.1503/cmaj.130727. Epub 2014 Apr 22.
Abstract
摘要
相似文献
1
Drug therapy for multiple sclerosis.多发性硬化症的药物治疗
CMAJ. 2014 Aug 5;186(11):833-40. doi: 10.1503/cmaj.130727. Epub 2014 Apr 22.
2
[Aspects of immunosuppressive therapy of multiple sclerosis].
Psychiatr Neurol Med Psychol Beih. 1975;20-21:23-6.
3
Immunosuppressive treatment of multiple sclerosis.多发性硬化症的免疫抑制治疗
NITA. 1985 Nov-Dec;8(6):503-5.
4
Azathioprine and methotrexate in multiple sclerosis.硫唑嘌呤和甲氨蝶呤用于治疗多发性硬化症。
J Neurol Sci. 2004 Aug 15;223(1):29-34. doi: 10.1016/j.jns.2004.04.016.
5
[Approaches to the treatment of malignant and progressive multiple sclerosis].
Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(7 Suppl 2):114-21.
6
Disease modification in multiple sclerosis.多发性硬化症的疾病修饰
J Pak Med Assoc. 2003 Dec;53(12):612-5.
7
Medications used in the treatment of multiple sclerosis.
Phys Med Rehabil Clin N Am. 1999 May;10(2):437-46, ix.
8
9
Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?时间在多发性硬化症中至关重要：早期治疗和长期随访能否确保每个人都能从多发性硬化症的最新进展中获益？
J Neurol Neurosurg Psychiatry. 2018 Aug;89(8):844-850. doi: 10.1136/jnnp-2017-317509. Epub 2018 Apr 4.
10
A review of systemic nonspecific immunosuppressive treatment of multiple sclerosis.
Neurology. 1978 Sep;28(9 Pt 2):132-9. doi: 10.1212/wnl.28.9_part_2.132.
引用本文的文献
1
Acetyl 11-Keto Beta-Boswellic Acid Improves Neurological Functions in a Mouse Model of Multiple Sclerosis.乙酰-11-酮基-β-乳香酸改善多发性硬化小鼠模型的神经功能
Inflammation. 2024 Nov 2. doi: 10.1007/s10753-024-02176-2.
2
Rehabilitation therapy versus drug-only therapy in patients with multiple sclerosis.多发性硬化症患者的康复治疗与单纯药物治疗的比较。
Turk J Med Sci. 2023 Jul 17;54(1):157-164. doi: 10.55730/1300-0144.5776. eCollection 2024.
3
Human umbilical cord mesenchymal stem cell-derived exosomes alleviate the severity of experimental autoimmune encephalomyelitis and enhance lag-3 expression on foxp3 + CD4 + T cells.人脐带间充质干细胞来源的外泌体可减轻实验性自身免疫性脑脊髓炎的严重程度，并增强 Foxp3+CD4+T 细胞上的 Lag-3 表达。
Mol Biol Rep. 2024 Apr 16;51(1):522. doi: 10.1007/s11033-024-09433-5.
4
Multiple Sclerosis-A Demyelinating Disorder and Its Dental Considerations-A Literature Review with Own Case Report.多发性硬化症——一种脱髓鞘疾病及其牙科相关考量——一篇文献综述及病例报告
Brain Sci. 2023 Jun 29;13(7):1009. doi: 10.3390/brainsci13071009.
5
Effect of applying inclusion and exclusion criteria of phase III clinical trials to multiple sclerosis patients in routine clinical care.将 III 期临床试验的纳入和排除标准应用于常规临床护理中的多发性硬化症患者的效果。
Mult Scler. 2021 Oct;27(12):1852-1863. doi: 10.1177/1352458520985118. Epub 2021 Jan 20.
6
Targeting Chemokines and Chemokine Receptors in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.靶向趋化因子及趋化因子受体治疗多发性硬化症和实验性自身免疫性脑脊髓炎
J Inflamm Res. 2020 Sep 29;13:619-633. doi: 10.2147/JIR.S270872. eCollection 2020.
7
Assessment of ability of human adipose derived stem cells for long term overexpression of IL-11 and IL-13 as therapeutic cytokines.评估人脂肪来源干细胞长期过表达白细胞介素-11和白细胞介素-13作为治疗性细胞因子的能力。
Cytotechnology. 2020 Oct;72(5):773-784. doi: 10.1007/s10616-020-00421-8. Epub 2020 Sep 15.
8
Designing drug-free biodegradable nanoparticles to modulate inflammatory monocytes and neutrophils for ameliorating inflammation.设计无药物的可生物降解纳米颗粒以调节炎症性单核细胞和中性粒细胞，从而改善炎症。
J Control Release. 2019 Apr 28;300:185-196. doi: 10.1016/j.jconrel.2019.02.025. Epub 2019 Feb 27.
9
Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey.在意大利多发性硬化症患者样本中干扰生育决策的因素：一项探索性在线调查。
J Neurol. 2019 Mar;266(3):707-716. doi: 10.1007/s00415-019-09193-4. Epub 2019 Jan 16.
10
Neural Stem Cell-Based Regenerative Approaches for the Treatment of Multiple Sclerosis.基于神经干细胞的再生方法治疗多发性硬化症。
Mol Neurobiol. 2018 Apr;55(4):3152-3171. doi: 10.1007/s12035-017-0566-7. Epub 2017 May 2.
本文引用的文献
1
Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.口服与静脉注射类固醇治疗多发性硬化症复发的比较
Cochrane Database Syst Rev. 2012 Dec 12;12:CD006921. doi: 10.1002/14651858.CD006921.pub3.
2
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.阿仑单抗与干扰素β1a 作为复发缓解型多发性硬化症一线治疗的比较：一项随机对照 3 期试验。
Lancet. 2012 Nov 24;380(9856):1819-28. doi: 10.1016/S0140-6736(12)61769-3. Epub 2012 Nov 1.
3
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.阿仑单抗治疗缓解复发型多发性硬化症患者：一项疾病修饰治疗后随机对照 3 期试验。
Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.
4
Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study.多发性硬化症患者使用醋酸格拉替雷后的妊娠和胎儿结局：一项前瞻性观察性多中心研究。
BMC Neurol. 2012 Oct 22;12:124. doi: 10.1186/1471-2377-12-124.
5
The mechanism of action of glatiramer acetate in multiple sclerosis and beyond.醋酸格拉替雷在多发性硬化症及其他疾病中的作用机制。
Autoimmun Rev. 2013 Mar;12(5):543-53. doi: 10.1016/j.autrev.2012.09.005. Epub 2012 Oct 7.
6
Scoring treatment response in patients with relapsing multiple sclerosis.评估复发型多发性硬化症患者的治疗应答。
Mult Scler. 2013 Apr;19(5):605-12. doi: 10.1177/1352458512460605. Epub 2012 Sep 25.
7
Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.多发性硬化症患者血清那他珠单抗浓度及抗那他珠单抗抗体的临床意义。
Mult Scler. 2013 Apr;19(5):593-600. doi: 10.1177/1352458512460604. Epub 2012 Sep 19.
8
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.口服 BG-12 治疗复发型多发性硬化症的安慰剂对照 3 期研究。
N Engl J Med. 2012 Sep 20;367(12):1098-107. doi: 10.1056/NEJMoa1114287.
9
Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.干扰素β治疗与复发缓解型多发性硬化患者残疾进展的相关性。
JAMA. 2012 Jul 18;308(3):247-56. doi: 10.1001/jama.2012.7625.
10
Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.芬戈莫德疗法对多发性硬化症患者磁共振成像结果的影响。
Arch Neurol. 2012 Oct;69(10):1259-69. doi: 10.1001/archneurol.2012.1051.
Zotero 插件